To secure its position as a life science superpower, the UK will need to increase its influence on the global stage by providing international leadership on issues of importance to the life science industry. Furthermore, it is vital that the UK’s domestic policies ensure that it can remain competitive versus other leading life science hubs.
International research
To address the major health challenges of our time, the global pharmaceutical sector is pioneering cutting-edge science that can help develop new treatments and cures for diseases from cancer to dementia, as well as preventing disease through the latest generation of vaccines.
Intellectual property (IP)
The fundamental role of IP for protecting and promoting UK scientific innovation and securing the UK’s ambition to be a life science super power
International trade
The ABPI is working to ensure that the UK has the best relationship with the EU for patients, public health and the life sciences sector.
International regulation
The UK is part of an increasingly competitive and changing global ecosystem. Regulatory regimes need to be dynamic and constantly evolving to adapt to the latest scientific and technological advances, as well as factors such as environmental sustainability and data privacy.
International, trade and IP publications
-
WTO Twelfth Ministerial Conference: A Critical Opportunity to Strengthen the Global Trade and Health Agenda
The WTO’s Twelfth Ministerial Conference (MC12) presents an opportunity for WTO members to formalize and pursue a robust trade and health agenda that builds on these principles and further strengthens the open and rules-based international trading system in response to COVID-19 and future health crises.
-
Creating trade policy for a life sciences superpower
To achieve the Government’s ambition for the UK to thrive as a life sciences superpower, the Association of the British Pharmaceutical Industry (ABPI) believes the Government should establish three core pillars for its trade policy for pharmaceuticals.